Gilead Sciences (GILD)
130.34
+0.06 (0.05%)
Upcoming Events
Latest Headlines
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
July 21, 2026 4:05 PM - BizWire
Gilead to present lenacapavir HIV trial data at AIDS 2026
July 21, 2026 10:00 AM - StreetInsider
Gilead and Merck HIV pill shows strong results in Phase 3 trials
July 21, 2026 10:00 AM - StreetInsider
Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
July 21, 2026 10:00 AM - BizWire
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
July 21, 2026 10:00 AM - BizWire
Leerink Downgrades Gilead Sciences (GILD) to Market Perform
July 20, 2026 4:17 PM - StreetInsider
Form 4 GILEAD SCIENCES, INC. For: Jul 15 Filed by: Dickinson Andrew D
July 16, 2026 6:08 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Jul 15 Filed by: Mercier Johanna
July 16, 2026 4:55 PM - SEC Filing
Form 144 GILEAD SCIENCES, INC. Filed by: Mercier Johanna
July 15, 2026 4:13 PM - SEC Filing
Form 144 GILEAD SCIENCES, INC. Filed by: Dickinson Andrew D
July 15, 2026 4:11 PM - SEC Filing
Gilead Sciences (GILD) PT Lowered to $166 at Morgan Stanley
July 8, 2026 8:08 AM - StreetInsider
Gilead Sciences (GILD) PT Lowered to $120 at RBC Capital
July 7, 2026 7:55 AM - StreetInsider
Gilead Sciences (GILD) PT Lowered to $156 at Truist Securities
July 7, 2026 7:09 AM - StreetInsider
HSBC Upgrades Gilead Sciences (GILD) to Buy
July 6, 2026 1:35 AM - StreetInsider
Form 4 GILEAD SCIENCES, INC. For: Jul 01 Filed by: O'Day Daniel Patrick
July 2, 2026 4:14 PM - SEC Filing
FDA clears Gilead's Trodelvy for first-line metastatic TNBC
June 24, 2026 4:29 PM - StreetInsider
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
June 24, 2026 4:29 PM - BizWire
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
June 24, 2026 8:30 AM - StreetInsider
EU approves Gilead's Trodelvy for first-line metastatic TNBC
June 23, 2026 7:45 AM - StreetInsider
European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
June 23, 2026 7:45 AM - BizWire
Gilead Sciences (GILD) Reiterated at Overweight by Cantor Fitzgerald: Yeztugo Total TRx Down
June 22, 2026 7:39 AM - StreetInsider
Gilead Sciences (GILD) Reiterated at Overweight by Cantor Fitzgerald post CFO Chat
June 17, 2026 6:54 AM - StreetInsider
Form 4 GILEAD SCIENCES, INC. For: Jun 15 Filed by: Mercier Johanna
June 16, 2026 6:02 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Jun 15 Filed by: Dickinson Andrew D
June 16, 2026 5:53 PM - SEC Filing
Gilead Sciences (GILD) Reiterated at Overweight by Cantor Fitzgerald on FDA Approval
June 16, 2026 7:05 AM - StreetInsider
Gilead Sciences: FDA accepts GILEAD application for once-weekly oral HIV prevention pill
June 15, 2026 4:34 PM - StreetInsider
U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
June 15, 2026 4:34 PM - BizWire
Form 144 GILEAD SCIENCES, INC. Filed by: Dickinson Andrew D
June 15, 2026 4:31 PM - SEC Filing
Form 144 GILEAD SCIENCES, INC. Filed by: Mercier Johanna
June 15, 2026 4:09 PM - SEC Filing
Gilead donates remdesivir to Uganda for Ebola outbreak response
June 12, 2026 8:30 AM - StreetInsider
Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
June 12, 2026 8:30 AM - BizWire
Form 4 GILEAD SCIENCES, INC. For: Jun 10 Filed by: Berger Dietmar
June 11, 2026 6:36 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Jun 10 Filed by: Cain Wettan Keeley M
June 11, 2026 6:34 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Jun 10 Filed by: Dickinson Andrew D
June 11, 2026 6:33 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Jun 10 Filed by: Mercier Johanna
June 11, 2026 6:31 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Jun 10 Filed by: O'Day Daniel Patrick
June 11, 2026 6:30 PM - SEC Filing
National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
June 11, 2026 8:30 AM - BizWire
Gilead Sciences (GILD) Reiterated at Overweight by Cantor Fitzgerald
June 9, 2026 6:54 AM - StreetInsider
Gilead and Merck announce successful HIV treatment trial results
June 8, 2026 4:35 PM - StreetInsider
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
June 8, 2026 4:35 PM - BizWire
Merck and Gilead discontinue lung cancer drug combination trial
June 8, 2026 4:30 PM - StreetInsider
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
June 8, 2026 4:30 PM - BizWire
RBC Capital: 'Where Does Gilead Sciences (GILD) Stand With In Vivo CAR-T?'
June 8, 2026 9:03 AM - StreetInsider
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
June 5, 2026 3:00 AM - BizWire
Gilead and Lakefront complete $1.675 billion Ouro Medicines acquisition
June 4, 2026 4:15 PM - StreetInsider
GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE
June 4, 2026 4:15 PM - StreetInsider
Form 4 GILEAD SCIENCES, INC. For: Jun 01 Filed by: O'Day Daniel Patrick
June 2, 2026 6:04 PM - SEC Filing
GILD reports positive results for Livdelzi in PBC patients with mild ALP elevation
June 2, 2026 8:30 AM - StreetInsider
Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
June 2, 2026 8:30 AM - BizWire
Form 144 GILEAD SCIENCES, INC. Filed by: O'Day Daniel Patrick
June 1, 2026 4:45 PM - SEC Filing
RBC Capital Reiterates Sector Perform Rating on Gilead Sciences (GILD)
June 1, 2026 7:47 AM - StreetInsider
Gilead's Livdelzi shows sustained liver marker improvement in PBC study
May 27, 2026 2:00 AM - StreetInsider
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)
May 27, 2026 2:00 AM - BizWire
FDA approves Gilead's Hepcludex as first HDV treatment in U.S.
May 22, 2026 2:00 PM - StreetInsider
FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
May 22, 2026 2:00 PM - BizWire
FDA Approves Hepcludex injection to treat chronic Hepatitis Delta virus infection in adults w/o Cirrhosis or w/ compensated Cirrhosis
May 22, 2026 1:42 PM - StreetInsider
China holds roundtable with over 50 foreign pharmaceutical firms
May 22, 2026 9:54 AM - StreetInsider
Gilead receives EU panel backing for Trodelvy in breast cancer treatment
May 22, 2026 7:47 AM - StreetInsider
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
May 22, 2026 7:47 AM - BizWire
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
May 21, 2026 5:00 PM - BizWire
Gilead Sciences completes $3.15 billion Tubulis acquisition
May 21, 2026 9:30 AM - StreetInsider
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
May 21, 2026 9:30 AM - BizWire
Gilead Sciences extends WHO partnership to fight visceral leishmaniasis
May 21, 2026 5:55 AM - StreetInsider
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
May 21, 2026 3:30 AM - BizWire
Gilead Sciences issues $3 billion in senior notes across four tranches
May 20, 2026 4:19 PM - StreetInsider
Form 8-K GILEAD SCIENCES, INC. For: May 14
May 20, 2026 4:16 PM - SEC Filing
Maxim Group Upgrades Gilead Sciences (GILD) to Buy
May 20, 2026 8:09 AM - StreetInsider
Form 4 GILEAD SCIENCES, INC. For: May 15 Filed by: Dickinson Andrew D
May 18, 2026 5:51 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: May 15 Filed by: Mercier Johanna
May 18, 2026 5:46 PM - SEC Filing
Form 424B5 GILEAD SCIENCES, INC.
May 18, 2026 4:26 PM - SEC Filing
Form 144 GILEAD SCIENCES, INC. Filed by: Mercier Johanna
May 15, 2026 4:14 PM - SEC Filing
Form 144 GILEAD SCIENCES, INC. Filed by: Dickinson Andrew D
May 15, 2026 4:12 PM - SEC Filing
Gilead Prices $3 Billion of Senior Unsecured Notes
May 14, 2026 9:21 PM - BizWire
Form FWP GILEAD SCIENCES, INC. Filed by: GILEAD SCIENCES, INC.
May 14, 2026 5:12 PM - SEC Filing
Form 424B5 GILEAD SCIENCES, INC.
May 14, 2026 8:46 AM - SEC Filing
Gilead to present 29 abstracts on liver disease treatments at EASL 2026
May 13, 2026 8:30 AM - StreetInsider
Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026
May 13, 2026 8:30 AM - BizWire
RBC Capital on Gilead Sciences (GILD): 'What To Look For In Upcoming UC Readout'
May 11, 2026 8:42 AM - StreetInsider
Gilead Sciences (GILD) PT Lowered to $168 at Morgan Stanley
May 11, 2026 8:27 AM - StreetInsider
Form 13F-HR GILEAD SCIENCES, INC. For: Mar 31
May 8, 2026 5:01 PM - SEC Filing
Gilead Sciences (GILD) PT Lowered to $122 at RBC Capital
May 8, 2026 7:30 AM - StreetInsider
Gilead Sciences (GILD) PT Raised to $157 at Truist Securities
May 8, 2026 7:19 AM - StreetInsider
Gilead Sciences (GILD) PT Lowered to $168 at Morgan Stanley
May 8, 2026 6:18 AM - StreetInsider
Stocks expected to have increasing option volume: GILD OPEN SYNA ARLO HUBS FROG SG WEN FIS MXK MELI MCHP RILY RNG QCOM SERV LOCO YELP REAL IREN GSAT MSI
May 8, 2026 4:42 AM - StreetInsider
Form S-8 GILEAD SCIENCES, INC.
May 7, 2026 5:14 PM - SEC Filing
Form 10-Q GILEAD SCIENCES, INC. For: Mar 31
May 7, 2026 5:12 PM - SEC Filing
Gilead Sciences (GILD) Tops Q1 EPS by 13c, Beats on Revenue; Offers FY26 Guidance
May 7, 2026 4:07 PM - StreetInsider
Form 8-K GILEAD SCIENCES, INC. For: May 07
May 7, 2026 4:03 PM - SEC Filing
Gilead Sciences Announces First Quarter Financial Results
May 7, 2026 4:01 PM - BizWire
Gilead Sciences (GILD) call put ratio 1 call to 1.3 puts with a focus on May 8 weekly 135 calls into quarter results
May 7, 2026 10:38 AM - StreetInsider
Gilead Sciences (GILD) call put ratio 1.9 calls to 1 put with a focus on June options into quarter results
May 6, 2026 11:08 AM - StreetInsider
Form 4 GILEAD SCIENCES, INC. For: Apr 30 Filed by: Bluestone Jeffrey
May 4, 2026 4:40 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Apr 30 Filed by: BARTON JACQUELINE K
May 4, 2026 4:37 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Apr 30 Filed by: Horning Sandra
May 4, 2026 4:33 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Apr 30 Filed by: LOVE TED W
May 4, 2026 4:29 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Apr 30 Filed by: Rodriguez Javier
May 4, 2026 4:25 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Apr 30 Filed by: WELTERS ANTHONY
May 4, 2026 4:23 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Apr 30 Filed by: MANWANI HARISH
May 4, 2026 4:21 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Apr 30 Filed by: Kramer Kelly A.
May 4, 2026 4:19 PM - SEC Filing
Form 8-K GILEAD SCIENCES, INC. For: Apr 30
May 4, 2026 4:07 PM - SEC Filing
Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences
May 1, 2026 6:00 AM - BizWire
Form SCHEDULE 13G GILEAD SCIENCES, INC. Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 29, 2026 6:42 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Apr 28 Filed by: O'Day Daniel Patrick
April 29, 2026 5:54 PM - SEC Filing
FDA grants priority review to Gilead's HIV treatment combination
April 29, 2026 8:30 AM - StreetInsider
U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir
April 29, 2026 8:30 AM - BizWire
Form 144 GILEAD SCIENCES, INC. Filed by: O'Day Daniel Patrick
April 28, 2026 4:13 PM - SEC Filing
Form 8-K GILEAD SCIENCES, INC. For: Apr 28
April 28, 2026 8:57 AM - SEC Filing
Gilead Sciences completes $7.8 billion Arcellx acquisition
April 28, 2026 8:45 AM - StreetInsider
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
April 28, 2026 8:45 AM - BizWire
Full Article List
